Mannkind Corp
NASDAQ: MNKD
$7.39
-$0.05 (-0.7%)
Closing Price on November 7, 2024
MNKD Articles
Short sellers are often active in biotech stocks, and we have seen some excessive short interest activity in the latest report.
Published:
Short sellers might be inclined to bet against biotech companies because of their volatile behavior on the charts.
Published:
Jon OggMannKind Corp. (NASDAQ: MNKD) was supposed to be a huge winner on this week’s news that Sanofi (NYSE: SNY) will become its global partner for its inhalable insulin Afrezza. There has...
Published:
Last Updated:
ThinkstockMannKind Corp. (NASDAQ: MNKD) was supposed to be in the news for its earnings report. Instead, we got news of its strategy on how to get its Afrezza inhalable insulin to the market. The...
Published:
ThinkstockStocks hit a new all-time this last week on the heels of a strong unemployment and jobs number. Now investors have to decide whether the next year or more will simply be a sustained bull...
Published:
24/7 Wall St. ran a poll for investors this week on where MannKind shares would go into 2015, and the results were overwhelmingly bullish.
Published:
These are the top analyst upgrades, downgrades and initiations from Wall Street firms on Tuesday, July 1. They include Amicus Therapeutics, Juniper Networks, Netflix, MannKind and Xerox.
Published:
ThinkstockMannKind Corp. (NASDAQ: MNKD) has seen its shares surge on news that it has finally won U.S. Food & Drug Administration backing. This FDA approval for Type 1 and 2 diabetes is being...
Published:
After markets closed last Friday, MannKind announced that the FDA had approved Afrezza, a rapid-acting, inhaled insulin powder that improves glycemic control in adults with diabetes.
Published:
Last Updated:
ThinkstockThe U.S. Food and Drug Administration (FDA) late Friday afternoon announced that it has approved Afrezza, a rapid-acting, inhaled insulin power that improves glycemic control in adults with...
Published:
Last Updated:
ThinkstockStocks have pulled back from their all-time highs after escalation of civil war in Iraq, but Friday managed to close higher. Investors remain bullish, and they keep hearing that the bull...
Published:
MannKind is just about a month away from the FDA decision on Afrezza as the first inhalable insulin treatment for diabetes. Afrezza almost certainly will become a blockbuster drug if approved.
Published:
These are the top Wall Street analyst upgrades, downgrades and initiations for Friday, June 13, 2014. They include Alcoa, Intel, Lululemon, MannKind, Marathon and Occidental Petroleum.
Published:
ThinkstockShort sellers have many reasons to bet against a stock, some of which are hedging or part of a larger theme. Other reasons may be a bet against a company or sector, or in the case of...
Published:
ThinkstockStocks hit new highs this past week, only to sell off handily. Investors want gains, but they remain wary. 24/7 Wall St. reviews dozens of analyst research reports from Wall Street and...
Published: